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Haematuria: a problematic symptom   
In the UK, bladder cancer (BC) kills around 5600 people per year. The majority of these cases are 
men, as the disease is 2.5 times more frequent in males than females.  
Blood in the urine (haematuria) is the most common symptom, occurring in around 85% of 
cases. Patients may consult their GPs after noticing a change in the colour of their urine (occasionally 
referred to as ‘visible’, ‘gross’ or ‘macroscopic’ haematuria [VH]), while less obvious blood traces 
may be picked up by a routine urine test (‘non-visible’ or ‘microscopic’ haematuria [NVH]). Both 
types are associated with a small but not insignificant risk of bladder cancer, with NVH being more 
significant in older patients.[1]  
NICE guidelines (https://cks.nice.org.uk/urological-cancers-recognition-and-referral) 
currently recommend that all patients aged over 45 years with unexplained or recurrent VH are 
referred to the haematuria clinic or urology department via the urgent two-week pathway for 
suspected cancer. Patients over 60 should also be referred if they have NVH combined with other 
clinical signs such dysuria or a raised white cell count. However, in the UK only around 34% of BC 
patients are diagnosed through this urgent referral pathway. Patients who do not fall within the 
urgent referral guidelines or with vague symptoms may end up being diagnosed through a standard 
GP referral (28% of all BC cases) or as an emergency presentation (18%). 
(http://www.ncin.org.uk/publications/routes_to_diagnosis).  
Once a case of BC is suspected, the gold standard diagnostic test is visualisation of the 
bladder by cystoscopy. This procedure is reasonably sensitive and specific;(2) however, it is labour 
intensive, expensive (£243, code LB14E, NHS National Tariff 2018/19), can be embarrassing and 
painful, and carries risks such as infections, bleeding, damage to the bladder wall or to the urethra.  
Urine cytology, which looks for abnormalities in bladder cells exfoliated in urine, is a very 
specific test but with little added diagnostic value due to its low sensitivity.[2] In practice, it is often 
limited to selected patients; for example, those with persistent haematuria but negative cystoscopy. 
Further imaging, such as an abdominal and pelvic ultrasound or CT scan, may also be performed in 
these patients to exclude upper urinary tract cancers (kidney and ureter). 
Overall, only around 1 in 10 patients referred and investigated for haematuria are found to 
have BC, and very few have other urinary malignancies.[3] New tests to help identify haematuria 
patients who are at a higher risk of cancer would help improve the diagnostic pathway, reduce the 
number diagnosed by emergency presentation, lessen the burden on urology services and spare an 
invasive and costly examination, such as cystoscopy, to those who do not have cancer.   
Bladder cancer urinary tests: from lab to clinic 
Cancer is a multistep process during which cells accumulate a number of abnormalities, including 
changes in their DNA and in the type and amount of mRNA and proteins they produce. Overall 
bladder cancer cells may show hundreds of aberrations, some very common, others only found in a 
few cases. Because bladder cancer cells are in contact with urine and are shed into it, some of these 
alterations can be detected in urine samples from BC patients. A great effort is going into translating 
knowledge of these cancer-specific molecular changes into urinary tests for BC diagnosis (see Figure 
1). The challenge, however, is narrowing them down to a few key markers that can identify most 
cancers while ruling out most non-cancers. 
Many BC urinary tests require specialist laboratory expertise and complex, time-consuming, 
and costly methodologies. However, a few easy to use bladder cancer point-of-care (BC-POC) tests 
have reached the market (see Table 1).  Most BC-POC tests are lateral flow immunochromatographic 
assays, based on the principle of a liquid (urine) running along a surface lined with antibodies against 
a certain marker. They look and function similarly to home pregnancy tests, with results displayed as 
the presence/absence of a result line in the test window shortly (5–30 minutes) after the addition of 
a few drops of urine. In contrast to the others, Xpert® Bladder Cancer Detect is a polymerase chain 
reaction-based assay. A small volume (4.5 ml) of urine is added to a cartridge that is then loaded into 
a processing unit, with results available within 90 minutes.  
As BC-POC tests provide quick information on cancer risk without requiring specialist 
technical expertise, they would be ideal to use in primary care for triaging patients presenting with 
haematuria. However, implementation would first require meeting a number of essential 
requirements, detailed in Table 2.  
Disappointingly, initial trials indicate that the sensitivity of some BC-POC tests is too low to 
be clinically useful as a stand-alone test. For example, pooled data from thousands of patients 
showed an overall sensitivity of 56% (hazard ratio [HR] 95%; confidence interval [CI] 52–59%) for the 
BladderChek®[4], and 59% (HR 95%; CI 55–62%) for UBC-Rapid®[5], which suggests that these tests 
would miss around 1 in 2 cancers.  
In a similar pooled study,[6] BTAStat® fared better, with a 67% (HR 95%; CI 64–69%) 
sensitivity, while an initial assessment of Xpert® Bladder Cancer Detect showed a sensitivity in the 
65–83% range. For comparison, the sensitivity of white light cystoscopy is around 87% for papillary 
lesions, although it is lower (around 67%) for flat carcinoma-in-situ (CIS).[7] As the performance of 
BC-POC tests is not superior to the gold standard test, they are generally considered as an add-on to 
cystoscopy rather than a stand-alone test (for example, they could be useful to help identify CIS 
lesions missed by cystoscopy). Notably, extreme variability in test performance is observed between 
studies (see the large sensitivity range in Table 1) due to differences in design and patient selection, 
showing the need for a more systematic comparative evaluation of these or upcoming BC-POC tests 
in future. 
Evaluating BC-POC tests in the ‘real world’  
Funded by Cancer Research UK, the CanTest collaborative has recently developed a framework for 
the evaluation of cancer diagnostic tests, involving a five-phase iterative process.[8] This progresses 
from single tests, assessed in isolation in selected populations with high disease incidence, to direct 
comparisons of clinical and cost-effectiveness of several tests in a ‘real world’ clinically relevant 
population, where cancer prevalence is lower and confounding factors may be present. 
Most studies of BC-POC tests map to the earlier steps in this process, as they have looked at 
single test performance in patients with BC or under surveillance for a previous BC compared to 
healthy controls. These results are difficult to extrapolate to a primary care population for a number 
of reasons. Firstly, the performance of diagnostic tests is affected by disease prevalence, with a 
lower sensitivity and higher specificity more likely in low-prevalence populations (eg, primary care 
haematuria patients) compared to high-prevalence groups (eg, BC cases monitored for 
recurrence).[9]  
Secondly, numerous studies have shown that BC-POC tests are much better at spotting high 
grade and stage tumours rather than low grade superficial ones. Therefore, sensitivity in primary 
care haematuria patients and patients under surveillance for a previous BC may not be comparable if 
the cancer stage and grade composition differs in the two groups (for example, due to cancers being 
picked up at an earlier stage in patients monitored for recurrences).  
The specificity of BC-POC tests in primary care may also be lower than expected, based on 
studies using urine samples from healthy controls, because the presence of conditions that are 
common in primary care patients (eg, infection, inflammation, benign prostate disease and kidney 
stones) has been shown to increase the number of false positives [10, 11]. In addition, the rate of 
false positives of some BC-POC tests is increased by the presence of blood in the urine (see Table 1), 
which means that their specificity in patients presenting to their GP with severe haematuria may be 
worse than in patients under BC surveillance without haematuria. 
Overall, this complexity illustrates the crucial importance of conducting future research on 
BC-POC tests in a ‘real world’ primary care setting, using the CanTest framework as guidance.  
How good does a BC-POC test need to be? 
It is evident that any test for triaging patients with potential cancer symptoms needs to be highly 
accurate, but there is little consensus on what is an acceptable value of sensitivity and specificity. By 
mapping the full clinical pathway and modelling the downstream clinical and cost effectiveness of 
different test results (eg, false positives and false negatives), acceptable levels of accuracy and test 
costs in different clinical settings could be explored. This information would be extremely useful for 
guiding the development of future tests, and avoid wasting resources in trialling tests that are 
unlikely to achieve clinical and cost-effectiveness. 
Interestingly, an investigation looking at what minimal sensitivity would be considered 
acceptable to patients has shown that, despite being an invasive procedure, cystoscopy was 
preferred by some as it provided greater peace of mind.[12] According to the study, for a urinary 
test to be considered acceptable to most patients as a replacement of cystoscopy, the minimal 
sensitivity would need to be at least 90%. This study, however, focussed on BC patients undergoing 
cystoscopy for monitoring recurrences. Primary care patients with haematuria but no prior cancer 
diagnosis or experience of cystoscopy may hold a different perspective. 
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Figures/tables 
 
Figure 1. Types of bladder cancer markers (protein, DNA or mRNA-based) and examples of 
corresponding urinary tests and methodologies required. Key: FISH = fluorescence in situ 
hybridisation; RT-PCR = real time reverse transcription polymerase chain reaction; ELISA = enzyme-
linked immunosorbent assay; POC = point-of-care (POC options are underlined) 
 
Name of test Time to 
result 
Sensitivity Specificity Does presence of blood in urine 
affect test performance? 
BTAStat® 5 min 53–78 50–95 Yes 
BladderChek®  30 min 16–88 67–100 Yes/No 
UBC-Rapid® 10 min 38–78 58–97 No 
Xpert® Bladder 
Cancer Detect 
90 min 65–83 77–90 No 
BioNexia® BTA 5 min - - Yes 
BCM/PreventID® 10 min 57–89 - Yes 
 
Table 1. Bladder cancer point-of-care tests, specificity and sensitivity and effect of haematuria on 
test performance. For BTAStat®, BladderCheck®, UBC-Rapid® and Xpert® Bladder Cancer the range 
of sensitivity and specificity is based on reviewing 29 references. For BioNexia® BTA and 
BCM/PreventID®, no published data are currently available on sensitivity and specificity; figures 
for BCM/PreventID® are from the company website 
 
Test characteristic Rationale 
High sensitivity Low sensitivity would lead to cancers being missed 
High specificity Low specificity would cause unnecessary referrals 
Minimal training required To be performed by healthcare workers without 
specialist skills 
Minimal equipment required Small, practical to use, easy to maintain and service 
Easy and quick to perform To fit within the time constrains of primary care 
Quick results Ideally immediately or, if not, within a few days, to 
avoid delaying cancer diagnosis 
Outcome easily interpretable Clear positive or negative result to support clinical 
decision making 
Cost-effective To be economically viable from an NHS perspective 
Non invasive and acceptable to patients 
and clinicians  
To ensure a high up-take rate 
Overall patients benefit Taking into account harms of false negatives and 
additional procedures triggered by the test results 
 
Table 2. Essential characteristics of novel point of care tests to be used in primary care for triaging 
of patients with bladder cancer symptoms 
 
Key points 
• The management of patients presenting to their GP with unexplained haematuria is problematic; 
• A number of simple and quick bladder cancer point-of-care tests are available but it is unclear 
whether they are sensitive enough to be used as triage tests for haematuria patients;  
• Robust primary-care based trials to evaluate clinical and cost effectiveness in the relevant ‘real 
world’ population are needed to underpin implementation.  
 
